WallStreetZenWallStreetZen

NASDAQ: AGRX
Agile Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AGRX

Based on 2 analysts offering 12 month price targets for Agile Therapeutics Inc.
Min Forecast
$1.00+274.53%
Avg Forecast
$2.00+649.06%
Max Forecast
$3.00+1,023.6%

Should I buy or sell AGRX stock?

Based on 3 analysts offering ratings for Agile Therapeutics Inc.
Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AGRX stock forecasts and price targets.

AGRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 5%
5
BuyMaintains$3.00+1,023.60%2022-12-30
Maxim Group
Bottom 3%
3
Strong BuyUpgrades$1.00+274.53%2022-07-26
Maxim Group
Bottom 24%
24
HoldDowngradesN/AN/A2022-04-08

1 of 1

Forecast return on equity

Is AGRX forecast to generate an efficient return?
Company
N/A
Industry
0.06%
Market
28.66%

Forecast return on assets

Is AGRX forecast to generate an efficient return on assets?
Company
N/A
Industry
0.04%

AGRX earnings per share forecast

What is AGRX's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$0.17
Avg 3 year Forecast
$0.09

AGRX revenue forecast

What is AGRX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$24.2M+188.23%
Avg 2 year Forecast
$47.0M+458.97%
Avg 3 year Forecast
$75.5M+798.96%
AGRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AGRX revenue growth forecast

How is AGRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
107.03%
Industry
11.52%
Market
8.77%
AGRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AGRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AGRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
AGRX$0.27$2.00+649.06%Buy
COSM$2.99N/AN/A
CYTH$0.92$10.00+990.51%Strong Buy
ALIM$1.35$6.75+400.00%Buy
SISI$0.60N/AN/A
View Top Pharmaceutical Stocks

Agile Therapeutics Stock Forecast FAQ

Is Agile Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AGRX) stock is to Buy AGRX stock.

Out of 3 analysts, 1 (33.33%) are recommending AGRX as a Strong Buy, 1 (33.33%) are recommending AGRX as a Buy, 1 (33.33%) are recommending AGRX as a Hold, 0 (0%) are recommending AGRX as a Sell, and 0 (0%) are recommending AGRX as a Strong Sell.

If you're new to stock investing, here's how to buy Agile Therapeutics stock.

What is AGRX's earnings growth forecast for 2023-2025?

(NASDAQ: AGRX) Agile Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 15.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.49%.

Agile Therapeutics's earnings in 2023 is -$67,011,000.On average, 1 Wall Street analyst forecast AGRX's earnings for 2023 to be -$17,058,101, with the lowest AGRX earnings forecast at -$17,058,101, and the highest AGRX earnings forecast at -$17,058,101. On average, 1 Wall Street analyst forecast AGRX's earnings for 2024 to be -$6,904,470, with the lowest AGRX earnings forecast at -$6,904,470, and the highest AGRX earnings forecast at -$6,904,470.

In 2025, AGRX is forecast to generate $3,655,307 in earnings, with the lowest earnings forecast at $3,655,307 and the highest earnings forecast at $3,655,307.

What is AGRX's revenue growth forecast for 2023-2025?

(NASDAQ: AGRX) Agile Therapeutics's forecast annual revenue growth rate of 107.03% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 11.52%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.77%.

Agile Therapeutics's revenue in 2023 is $8,403,000.On average, 1 Wall Street analysts forecast AGRX's revenue for 2023 to be $983,683,844, with the lowest AGRX revenue forecast at $983,683,844, and the highest AGRX revenue forecast at $983,683,844. On average, 1 Wall Street analysts forecast AGRX's revenue for 2024 to be $1,907,664,333, with the lowest AGRX revenue forecast at $1,907,664,333, and the highest AGRX revenue forecast at $1,907,664,333.

In 2025, AGRX is forecast to generate $3,068,021,370 in revenue, with the lowest revenue forecast at $3,068,021,370 and the highest revenue forecast at $3,068,021,370.

What is AGRX's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: AGRX) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 0.04%.

What is AGRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AGRX price target, the average AGRX price target is $2.00, with the highest AGRX stock price forecast at $3.00 and the lowest AGRX stock price forecast at $1.00.

On average, Wall Street analysts predict that Agile Therapeutics's share price could reach $2.00 by Dec 30, 2023. The average Agile Therapeutics stock price prediction forecasts a potential upside of 649.06% from the current AGRX share price of $0.27.

What is AGRX's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: AGRX) Agile Therapeutics's current Earnings Per Share (EPS) is -$15.02. On average, analysts forecast that AGRX's EPS will be -$0.42 for 2023, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at -$0.42. On average, analysts forecast that AGRX's EPS will be -$0.17 for 2024, with the lowest EPS forecast at -$0.17, and the highest EPS forecast at -$0.17. In 2025, AGRX's EPS is forecast to hit $0.09 (min: $0.09, max: $0.09).

What is AGRX's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: AGRX) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.